Novel neuropilin 2-targeting biologic for the treatment of oral squamous cell carcinoma

Oral squamous cell carcinoma (OSCC) is the sixth most common cancer and a leading cause of cancer mortality in some countries. Recently, our laboratory identified the neuropilin-2 (NRP2) transmembrane glycoprotein as a novel target in OSCC and its associated vasculature in patient biopsies and mouse carcinogenesis models. NRP2 is a co-receptor for the angiogenic factor vascular endothelial growth factor (VEGF)-A with VEGFR2 and the lymphangiogenic factors VEGF-C/D with VEGFR3 and is abundantly expressed in growing endothelium.

Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics - June 17, 2021 Category: ENT & OMF Authors: AM Almazyad, Y Gao, S Shahrabi-Farahani, A Gartung, L Sui, R Das, DE Costea, RS Watnick, D Panigrahy, RM Adam, DR Bielenberg Source Type: research